Trials / Completed
CompletedNCT00193505
Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
Phase II Trial of Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in the Treatment of Patients With Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- SCRI Development Innovations, LLC · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this Multicenter trial, we will evaluate the feasibility, toxicity, and efficacy of treatment with 90Y Zevalin following a short course of salvage chemotherapy in patients with relapsed/refractory intermediate grade B-cell non-Hodgkin's lymphoma.
Detailed description
Upon determination of eligibility, patients will receive: * Ifosfamide + Carboplatin + Etoposide + Rituximab Patients showing no response to this combination regimen will receive 90Y Zevalin after two cycles or when progression is clearly documented. In responding patients, four cycles will be administered, followed by 90Y Zevalin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ifosfamide | |
| DRUG | Carboplatin | |
| DRUG | Etoposide | |
| DRUG | Rituximab | |
| DRUG | 90Y Zevalin |
Timeline
- Start date
- 2003-10-01
- Primary completion
- 2005-08-01
- Completion
- 2005-08-01
- First posted
- 2005-09-19
- Last updated
- 2011-05-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00193505. Inclusion in this directory is not an endorsement.